RNDP-001

N/A

Report date: 2025/09/19 20:01:00

Base Information

Drug NameRNDP-001
Drug Alias NameRNDP-001
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > iPSC-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Dopamine progenitor cell
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRyne Biotechnology Inc
China Registration ClassN/A

Develop Information

Active CompaniesCalifornia Institute For Regenerative MedicineKenai Therapeutics IncRyne Biotechnology Inc
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A